Opko Health (OPK) Shares Gap Up Following Insider Buying Activity
Opko Health Inc. (NASDAQ:OPK) gapped up prior to trading on Friday after an insider bought additional shares in the company. The stock had previously closed at $2.36, but opened at $2.42. Opko Health shares last traded at $2.51, with a volume of 10127834 shares traded.
Specifically, CEO Phillip Md Et Al Frost acquired 15,000 shares of Opko Health stock in a transaction on Monday, January 14th. The stock was acquired at an average price of $3.74 per share, for a total transaction of $56,100.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $11,477,876.74. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Vice Chairman Jane Ph D. Hsiao acquired 10,000 shares of Opko Health stock in a transaction on Thursday, January 31st. The shares were bought at an average price of $7.96 per share, with a total value of $79,600.00. Following the purchase, the insider now directly owns 24,455,147 shares in the company, valued at approximately $194,662,970.12. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 1,158,000 shares of company stock valued at $3,361,580. 42.74% of the stock is currently owned by insiders.
A number of research firms have weighed in on OPK. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Friday, November 30th. ValuEngine upgraded Opko Health from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Barrington Research reiterated a “buy” rating and set a $5.00 price objective on shares of Opko Health in a research note on Thursday, February 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Opko Health currently has a consensus rating of “Hold” and a consensus price target of $9.67.
Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Opko Health by 1.4% in the 4th quarter. BlackRock Inc. now owns 30,276,662 shares of the biotechnology company’s stock valued at $91,133,000 after purchasing an additional 408,951 shares in the last quarter. Vanguard Group Inc increased its stake in shares of Opko Health by 2.1% in the 3rd quarter. Vanguard Group Inc now owns 29,660,750 shares of the biotechnology company’s stock valued at $102,626,000 after purchasing an additional 614,442 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Opko Health by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 29,660,750 shares of the biotechnology company’s stock valued at $102,626,000 after purchasing an additional 614,442 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Opko Health by 25.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,440,784 shares of the biotechnology company’s stock valued at $15,363,000 after purchasing an additional 897,406 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Opko Health by 4.2% in the 4th quarter. Geode Capital Management LLC now owns 4,078,397 shares of the biotechnology company’s stock valued at $12,275,000 after purchasing an additional 165,517 shares in the last quarter. Hedge funds and other institutional investors own 23.73% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/opko-health-opk-shares-gap-up-following-insider-buying-activity/2896060.html.
Opko Health Company Profile (NASDAQ:OPK)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Featured Story: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.